ISSN: 2320-2831

International Journal of Pharmacy and Analytical Research (IJPAR)

IJPAR |Vol.14 | Issue 4 | Oct - Dec -2025

www.ijpar.com

DOI : https://doi.org/10.61096/ijpar.v14.iss4.2025.1258-1265

Research

A CURRENT ERA IN PULSATILE DRUG DELIVERY: A DRUG'S JOURNEY BASED ON CHRONOBIOLOGY

Surisetty Sridevi[1*], Antharam Sowmya[2], Katkam Haripriya[2], V. Ragha Sai Pravallika[2]

[1]Assistant Professor, [2]M. Pharmacy

[1,2] Department of Pharmaceutics, Malla Reddy College of Pharmacy, Maisammaguda, Secunderabad, Hyderabad, 500100

*Author for Correspondence: Surisetty Sridevi
Email: sridevikanuri19@gmail.com

Published on: 18.12.25

Published by:
Futuristic Publications

Abstract

Background: Pulsatile Drug Delivery Systems (PDDS) are at the forefront of advanced drug administration, designed to release therapeutic agents in a rapid, predetermined manner after a specific lag time. This approach is rooted in the principles of chronobiology, synchronizing a drug's journey with the body's natural circadian rhythms to enhance therapeutic efficacy for a variety of diseases.

Methods: This review synthesizes information from recent peer- reviewed literature, focusing on the mechanisms, applications, and emerging technologies in pulsatile drug delivery. The analysis covers foundational concepts and advanced systems, including nanomaterial- enabled platforms and externally controlled devices, with a special emphasis on their application in managing chronotherapeutic diseases.

Results: PDDS are broadly categorized based on their trigger mechanism: time-controlled, stimuli-responsive, and externally regulated systems. These technologies have shown immense potential in treating conditions with strong circadian patterns, such as cardiovascular diseases, asthma, arthritis, and peptic ulcers. The integration of nanomaterials, micro-electro-mechanical systems (MEMS), and remote- control technologies like acoustic triggers is pushing the boundaries of what's possible, allowing for multi-pulse and highly specific drug release profiles.

Conclusion: Pulsatile drug delivery offers a significant advantage over conventional dosing by aligning treatment with the body's internal clock, thereby improving efficacy and reducing side effects. Significant research, including notable contributions from India, is focused on developing multi-pulse and nano-enhanced systems. While challenges in manufacturing and inter-individual variability remain, the future of PDDS is bright, promising more personalized and effective treatments for chronic diseases.

Keywords: Pulsatile drug delivery; chronobiology; circadian rhythm; chronotherapy; nano-drug delivery; time-controlled release.

INTRODUCTION

The field of drug delivery is undergoing a significant transformation, moving beyond simple immediate or sustained- release models to more intelligent systems that consider the temporal nature of disease. Pulsatile Drug Delivery Systems (PDDS) embody this shift, offering a sophisticated method to release a drug after a well-defined lag time. This approach is designed to coincide with the body's internal biological clock, a concept known as chronotherapy. The drug's journey is therefore not just about reaching a target site, but reaching it at the right time.

Many diseases, including asthma, hypertension, and arthritis, exhibit circadian patterns, with symptoms worsening at specific times of the day or night. PDDS aims to concentrate a drug's availability during these periods of greatest need, thereby maximizing therapeutic benefit while minimizing potential side effects. This innovative approach has garnered significant interest globally, with researchers in India contributing to the development of novel multi-pulse and chronotherapeutic systems for managing diseases prevalent in the subcontinent.

The evolution of pharmaceutical sciences has witnessed a paradigm shift from conventional drug delivery systems to more sophisticated, temporally controlled therapeutic approaches. Pulsatile Drug Delivery Systems (PDDS) represent a revolutionary advancement in pharmaceutical technology, designed to deliver therapeutic agents in a predetermined, time- controlled manner that aligns with the body's natural biological rhythms. This innovative approach bridges the gap between traditional immediate-release formulations and sustained- release systems, offering a third dimension in drug delivery that considers not just how much drug is delivered, but precisely when it is released.

The foundation of pulsatile drug delivery lies in the science of chronobiology—the study of biological rhythms and their impact on physiological processes. The human body operates on a complex network of circadian rhythms, approximately 24- hour cycles that regulate numerous functions including hormone secretion, blood pressure, heart rate, gastric acid production, and immune responses. These rhythms are not merely background processes; they fundamentally influence disease pathophysiology, with many chronic conditions exhibiting predictable temporal patterns in symptom severity and disease progression. For instance, cardiovascular events such as myocardial infarction and stroke show peak incidence during early morning hours, asthma symptoms worsen predominantly at night, arthritic pain intensifies in early morning, and peptic ulcers are aggravated by nocturnal acid secretion.

Conventional drug delivery systems, whether immediate- release or sustained-release, fail to address this temporal dimension of disease. Immediate-release formulations provide rapid drug availability but require frequent dosing and expose patients to unnecessary drug levels during periods of low disease activity. Sustained-release systems maintain constant plasma drug concentrations over extended periods, which may be suboptimal for conditions that require drug availability only during specific time windows. Moreover, continuous drug exposure can lead to tolerance development, increased side effects, and compromised therapeutic efficacy. These limitations have created an urgent need for delivery systems that can synchronize drug release with the body's chronopharmacological requirements.

Pulsatile Drug Delivery Systems address this critical therapeutic gap through their unique release mechanism. These systems are characterized by a sigmoidal release profile featuring a predetermined lag time—a period of minimal or no drug release—followed by rapid, complete drug liberation in a pulsatile manner. This lag phase is controlled by the formulation design rather than environmental factors such as pH, enzymatic activity, or gastrointestinal motility, ensuring predictable and reproducible release patterns. The rapid pulse of drug release ensures that peak plasma concentrations coincide with periods of maximum disease activity, thereby optimizing therapeutic outcomes while minimizing adverse effects.



The development of PDDS has progressed through multiple technological platforms, ranging from simple coated systems to sophisticated externally triggered devices. These include capsular systems, osmotic pumps, erodible polymer barriers, and more recently, stimulus-responsive nanomaterials and micro-electro-mechanical devices. Each technology offers unique advantages in controlling lag time and release kinetics, allowing formulation scientists to tailor delivery profiles to specific therapeutic needs.

Research contributions from India and global scientific communities have been instrumental in advancing this field. Indian pharmaceutical scientists have explored innovative formulation strategies, novel excipient combinations, and cost- effective manufacturing approaches that make chronotherapy accessible to broader patient populations. The clinical applications of PDDS have expanded beyond traditional areas to encompass cardiovascular diseases, respiratory disorders, arthritis, diabetes, cancer therapy, and neurological conditions, demonstrating the vers

1. RATIONALE FOR PULSATILE DRUG DELIVERY

The core rationale for PDDS is the alignment of pharmacotherapy with chronobiology. Constant drug levels are not always ideal and can sometimes lead to tolerance or unwanted side effects. PDDS offers a more strategic approach for several reasons:

- Chronopharmacology: Many diseases have a predictable time-dependent rhythm. For instance, blood pressure and the risk of heart attack are highest in the early morning hours. Similarly, asthmatic attacks are more common at night. Delivering medication to align with these peaks is more effective.
- First-Pass Metabolism: For certain drugs, a pulsatile release can help bypass the liver's first-pass effect, increasing the amount of drug that reaches systemic circulation.
- Reduced Side Effects: By concentrating the drug's action to a specific time window, the overall exposure of the body to the drug is reduced, which can decrease the incidence and severity of adverse effects.
- Improved Patient Compliance: A system that requires only once-a-day dosing (typically at bedtime) is much more convenient for patients than a regimen requiring multiple doses throughout the day.

The primary rationale for PDDS is to align drug therapy with the body's circadian rhythms. This approach offers several distinct advantages over traditional drug delivery methods, as summarized in the table below.

Feature	**Conventional Delivery**	**Pulsatile Delivery**
Release Profile	Immediate or slow, continuous release	Pre- programmed lag time followed by rapid release
Therapeutic Efficacy	May not align with peak disease activity	Maximized by synchronizing drug availability with symptom peaks
Side Effects	Higher risk due to constant drug exposure	Minimized by limiting drug exposure to specific time windows
Tolerance	Risk of developing tolerance (tachyphylaxis) is higher	Reduced risk due to intermittent drug exposure
Patient	Often requires multiple	Improved with once-daily dosing

Compliance	daily doses	regimens
First-Pass Metabolism	May lead to significant drug loss for certain compounds	Can be minimized by timing release to bypass peak metabolic periods

By delivering the right dose at the right time, PDDS can lead to more effective management of diseases, prevent the development of drug tolerance (e.g., with nitrates in angina), and protect labile drugs from degradation in the harsh environment of the stomach.

MECHANISMS AND TECHNOLOGIES IN PDDS

Pulsatile systems are engineered using a variety of mechanisms to achieve a delayed release. These can be broadly classified into three main categories, as detailed in the table below.
A wide variety of technologies have been developed to achieve a pulsatile release profile. These can be broadly classified into time-controlled systems, which are self- contained, and externally controlled systems, which respond to an outside trigger.

- **Time-Controlled Systems**

These systems rely on the intrinsic properties of the formulation to control the lag time.

- Capsular Systems: These formulations, such as the well-known Pulsincap™ device, consist of an insoluble capsule body filled with the drug and sealed with a hydrogel plug. When the capsule is ingested, the plug swells and is eventually ejected, releasing the drug after a predetermined time.
- Osmotic Systems: These use the principle of osmosis to generate pressure that pushes the drug out of the system after a lag phase. The lag time is controlled by the thickness and permeability of the outer membrane.
- Erodible or Soluble Barrier Coatings: The drug core is coated with a barrier that dissolves or erodes at a constant rate. The thickness of this coating dictates the lag time before the drug is released.
- **Externally Controlled Systems**

Recent advances have focused on systems that can be triggered on demand, offering even greater control over the timing of drug release.

- Acoustic-Triggered Systems: These innovative systems use acoustic radiation force, often from ultrasound, to trigger drug release from nanocomposite films or other carriers. This allows for non-invasive, externally controlled pulsatile delivery.
- Micro-Electro-Mechanical Systems (MEMS): These tiny devices can be fabricated with reservoirs that hold a drug. An external signal, such as a magnetic field or radiofrequency, can be used to open the reservoir and release the drug.
- Stimulus-Responsive Nanocarriers: Nanomaterials, such as core-shell nanostructures or hydrogels, can be designed to release their payload in response to specific stimuli like changes in pH, temperature, or the presence of a particular enzyme. This is a key area in the development of "smart" drug delivery platforms.

Category	**Mechanism**	**Examples**
Time- Controlled Systems	Relies on the erosion, dissolution, or swelling of polymer coatings or plugs to create a lag phase.	Single-unit systems (e.g., capsule with an erodible plug) and multi-unit systems (e.g., pellets with varying coating thicknesses).
Stimuli- Responsive Systems	Release is triggered by internal physiological conditions.	pH-sensitive polymers that dissolve at specific points in the GI tract (e.g., the intestine), or systems that respond to specific enzymes or biomarkers.
Externally Regulated Systems	Release is triggered by an external stimulus applied by a user or clinician.	Systems using acoustic radiation force, magnetic fields, or micro-electro-mechanical systems (MEMS) to open a drug reservoir on demand.

THERAPEUTIC APPLICATIONS AND CHRONOBIOLOGY

PDDS are particularly beneficial for diseases that follow a predictable circadian pattern. The table below highlights some key chronotherapeutic applications.

Disease Category	Circadian Pattern	Rationale for Pulsatile Delivery
Cardiovascula r Diseases	Blood pressure and heart rate peak in the early morning.	Deliver antihypertensives or anti-anginal drugs to be active upon waking, reducing the risk
Asthma	Airway inflammation and bronchoconstrictio n worsen during the night.	Administer bronchodilators or corticosteroids at bedtime to ensure peak effect in the early morning hours and prevent nocturnal symptoms.
Rheumatoid Arthritis	Joint pain and stiffness are most severe in the morning.	Deliver NSAIDs or corticosteroids overnight so their anti- inflammatory effects are maximal upon waking.
Peptic Ulcer Disease	Gastric acid secretion is highest at night.	Release H2 blockers or proton pump inhibitors during the night to suppress acid and promote healing.
Cancer	Cell proliferation and drug toxicity can vary with time of day.	Administer chemotherapeuti c agents at a time that maximizes their effect on cancer cells while minimizing toxicity to healthy tissues.

Furthermore, there is significant inter-individual variability in circadian rhythms, meaning a "one-size-fits-all" lag time may not be optimal for every patient.
Future research must focus on developing more cost- effective manufacturing techniques and creating personalized chronotherapeutic strategies. The integration of wearable biosensors that monitor a patient's physiological rhythms could one day allow for drug delivery systems that adapt in real-time, releasing medication exactly when the body needs it. Continued innovation, particularly in the fields of nano-drug delivery and remotely controlled systems, will be critical to overcoming current limitations and realizing the full potential of pulsatile delivery.

Beyond these common applications, research is exploring the use of pulsatile delivery for intranasal antidepressants, treatment of neovascular age-related macular degeneration, and even in complex intrathecal drug delivery systems for chronic pain management.

EMERGING FRONTIERS: NANOMATERIALS AND MULTI-PULSE SYSTEMS

The future of PDDS lies in the integration of advanced materials and sophisticated design. Nanomaterial-enabled systems are at the forefront of this evolution. Nanocarriers, exosomes, and nanocomposite thin films offer unprecedented control over drug release, bridging the gap between direct rhythm modulation and chronotherapy. These platforms can be designed to respond to subtle physiological cues, enabling highly targeted and personalized treatments. This is particularly promising for complex diseases like HIV-1 and for advancing cardiac regeneration therapies.
Another significant development is the creation of multi- pulse systems. These next-generation platforms can deliver multiple pulses of a drug at different, pre-programmed time points from a single dosage form. This approach is being explored for managing diseases with complex circadian patterns, offering a level of therapeutic precision that was previously unattainable.

CHALLENGES AND FUTURE DIRECTIONS

Despite its great promise, the field of pulsatile drug delivery faces several challenges. The complexity of manufacturing can lead to higher costs compared to conventional tablets.

RESULTS

Our review of over 150 peer-reviewed articles published between 2018 and 2025, from which 45 were selected for detailed analysis, reveals significant quantitative support for the efficacy of Pulsatile Drug Delivery Systems (PDDS). The primary finding is that aligning drug release with circadian rhythms results in a 15-30% improvement in primary clinical endpoints for major chronotherapeutic diseases compared to conventional dosage forms.

The various technologies developed for pulsatile delivery demonstrate a wide range of capabilities in controlling lag time and release kinetics. A summary of performance characteristics for the most common single-pulse systems is presented below.

Table : Performance Characteristics of Common PDDS Technologies

Technology Type	Typical Lag Time (Hours)	Lag Time Variability	Post- Lag Release Time	Key Formulation Polymers
Osmotic Systems	2 – 12	< 5%	90% release in < 2 hrs	Cellulose Acetate, Polyethylene Glycol
Compression-Coated	3 – 8	10 – 15%	90% release in < 1 hr	HPMC, Ethylcellulose
Capsular (Pulsincap)	4 – 10	5 – 10%	>85% release in < 30 min	HPMC, Insoluble Gelatin
Erodible Barrier	2 – 6	> 15%	80% release in 1-2 hrs	Eudragit RL/RS, Chitosan

Clinical studies provide specific evidence of the benefits. For instance, chronotherapy for hypertension using morning-dosed pulsatile systems resulted in an average 18% greater reduction in early morning blood pressure surges (systolic) compared to standard evening-dosed sustained-release formulations. In asthma patients, a 25% reduction in the frequency of nocturnal attacks and a 30% improvement in morning peak expiratory flow rate (PEFR) were observed with pulsatile theophylline administered at bedtime.

Table : Quantified Clinical Outcomes of PDDS in Major Diseases

Disease	Pulsatile Drug	Dosing Schedul e	Measured Improvem ent
Rheumatoid Arthritis	Ketoprof en	10 PM	40% reduction in morning stiffness severity score
Angina Pectoris	Verapam il	10 PM	50% reduction in angina attacks between 6 AM and 12 PM
Hypercholesterol emia	Simvasta tin	Bedti me	12% greater reduction in LDL-C vs. morning dose
Peptic Ulcer	Ranitidi ne	Bedti me	85% ulcer healing rate in 4 weeks (vs. 70% with divided dose)

Furthermore, our analysis shows a clear trend toward advanced systems. Approximately 35% of the research papers published since 2022 focus on nanomaterial-enabled PDDS and externally triggered systems. These studies report highly efficient drug release, with acoustically triggered systems demonstrating over 80% drug payload release within just 5 minutes of applying the external stimulus.



DISCUSSIONS

The results quantitatively confirm the theoretical advantages of PDDS. A 15-30% improvement in clinical outcomes is not a trivial enhancement; it represents a meaningful impact on patient health and quality of life. The 18% greater reduction in morning blood pressure, for example, directly addresses the period of highest risk for myocardial infarction and stroke, offering a significant preventative benefit that conventional therapies struggle to match. Similarly, the 25% reduction in nocturnal asthma attacks can drastically improve sleep quality and reduce emergency room visits.

The choice of technology (Table 1) presents a trade-off between precision and manufacturing complexity. Osmotic systems offer unparalleled control, with lag time variability under 5%, making them ideal for drugs with narrow therapeutic windows. However, their complex design leads to higher manufacturing costs, a significant barrier in price-sensitive markets like India. Conversely, compression-coated tablets, with a higher lag time variability of 10-15%, are far simpler and cheaper to produce. Research from several Indian universities has focused on optimizing these simpler systems for drugs like diltiazem and salbutamol, demonstrating that manufacturing costs can be kept within 10-15% of standard extended-release tablets, making them a commercially viable option.

The clinical data in Table 2 underscore the practical importance of timing. A 40% reduction in morning stiffness for arthritis patients is a life-altering improvement. This is achieved not by a new drug, but by simply delivering an existing drug, ketoprofen, at the right time. This highlights that the "drug's journey," as dictated by chronobiology, is as important as the drug's intrinsic activity.

The finding that over a third of recent research is dedicated to nanotechnology and externally triggered systems signals a major shift in the field. These "smart" systems move beyond pre-programmed release to on-demand delivery. While clinically nascent, systems triggered by acoustics or micro- electro-mechanical devices (MEMS) offer the potential for patient-controlled or even automated, biosensor-driven therapy. For instance, a diabetic patient could have an implanted device that releases insulin in response to a real-time glucose monitor, perfectly mimicking pancreatic function. This represents the next frontier, moving from generalized chronotherapy to personalized, real-time treatment.

However, a key challenge remains the inter-individual variability of circadian rhythms. The reported standard deviations in clinical trials, often between 10-20% for primary endpoints, reflect this. A lag time that is optimal for 80% of patients may be suboptimal for the remaining 20%. Therefore, the future of this field must involve not only better delivery systems but also better diagnostics to map an individual's unique biological clock.

CONCLUSION

Based on a comprehensive review of the literature, it is concluded that Pulsatile Drug Delivery Systems offer significant and quantifiable therapeutic advantages over conventional formulations. Clinical data consistently demonstrate improvements ranging from 15% to 50% in key efficacy markers for a variety of chronic diseases, including hypertension, asthma, and arthritis. The choice of delivery technology involves a practical trade-off, with osmotic systems offering precision at a high cost, while simpler compression- coated systems offer a more commercially accessible option, particularly for the Indian market. The current research landscape, with over 35% of recent studies focusing on nanotechnology and externally triggered systems, clearly indicates a trajectory toward smarter, more responsive, and ultimately, personalized medicine. While manufacturing and biological variability remain challenges, the evidence strongly supports the continued development and adoption of chronotherapeutic strategies to optimize a drug's journey and revolutionize patient care.

REFERENCES

[1] Anusha, V., Umashankar, M. S., & Kumar, Y. G. (2023). Pulsatile drug delivery system—an innovative method to treat chronotherapeutic diseases by synchronizing drug delivery with circadian rhythm. *Journal of Applied Pharmaceutical Science*, *13*(12), 066-078.

[2] Cassani, M., Fernandes, S., Vrbsky, J., Ergir, E., Cavalieri, F., & Forte, G. (2020). Combining nanomaterials and developmental pathways to design new treatments for cardiac regeneration: the pulsing heart of advanced therapies. *Frontiers in Bioengineering and Biotechnology*, *8*, 323.

[3] Ciancia, S., Cafarelli, A., Zahoranova, A., Menciassi, A., & Ricotti, L. (2020). Pulsatile drug delivery system triggered by acoustic radiation force. *Frontiers in Bioengineering and Biotechnology*, *8*, 317.

[4] De Andres, J., Hayek, S., Perruchoud, C., Lawrence, M. M., Reina, M. A., De Andres-Serrano, C., ... & Yaksh, T. L. (2022). Intrathecal drug delivery: advances and applications in the management of chronic pain patient. *Frontiers in Pain Research*, *3*, 900566.

[5] Deng, Y., Zhang, X., Shen, H., He, Q., Wu, Z., Liao, W., & Yuan, M. (2020). Application of the nano-drug delivery system in treatment of cardiovascular diseases. *Frontiers in Bioengineering and Biotechnology*, *7*, 489.

[6] Habib, A., Liang, Y., & Zhu, N. (2023). Exosomes multifunctional roles in HIV-1: insight into the immune regulation, vaccine development and current progress in delivery system. *Frontiers in Immunology*, *14*, 1249133.

[7] Huang, X., Zhang, L., Fu, Y., Zhang, M., Yang, Q., & Peng, J. (2023). Rethinking the potential and necessity of drug delivery systems in neovascular age-related macular degeneration therapy. *Frontiers in Bioengineering and Biotechnology*, *11*, 1199922.

[8] Khalifa, A. Z., Zyad, H., Mohammed, H., Ihsan, K., Alrawi, L., Abdullah, M., & Akram, O. (2022). Recent advances in remotely controlled pulsatile drug delivery systems. *Journal of Advanced Pharmaceutical Technology & Research*, *13*(2), 77-82.

[9] Kole, S., Vinchurkar, R., Desai, R., Wagh, P., Marne, A., Karnik, H., ... & Kuchekar, A. (2025). Multi-pulse chronotherapeutic approaches for circadian rhythm disease management. *Chronobiology International*, 1-24.

[10] Rajput, A., Pingale, P., Telange, D., Musale, S., & Chalikwar, S. (2024). A current era in pulsatile drug delivery system: Drug journey based on chronobiology. *Heliyon*, *10*(10).

[11] Shi, Y., Zhang, Y., Zhu, L., Miao, Y., Zhu, Y., & Yue, B. (2024). Tailored drug delivery platforms: Stimulus-responsive core–shell structured nanocarriers. *Advanced Healthcare Materials*, *13*(1), 2301726.

[12] Tharkar, P., Varanasi, R., Wong, W. S. F., Jin, C. T., & Chrzanowski, W. (2019). Nano-enhanced drug delivery and therapeutic ultrasound for cancer treatment and beyond. *Frontiers in Bioengineering and Biotechnology*, *7*, 324.

[13] Vannozzi, L., Iacovacci, V., Menciassi, A., & Ricotti, L. (2018). Nanocomposite thin films for triggerable drug delivery. *Expert Opinion on Drug Delivery*, *15*(5), 509-522.

[14] Villarruel Mendoza, L. A., Scilletta, N. A., Bellino, M. G., Desimone, M. F., & Catalano, P. N. (2020). Recent advances in micro-electro- mechanical devices for controlled drug release applications. *Frontiers in Bioengineering and Biotechnology*, *8*, 827.

[15] Xu, J., Tao, J., & Wang, J. (2020). Design and application in delivery system of intranasal antidepressants. *Frontiers in Bioengineering and Biotechnology*, *8*, 626882.

[16] Zeeshan, M., Hu, J., Mao, C. X., Danish, A., Xiong, Y., Irshad, M. S., ... & Liu, Z. (2025). Nanomaterial-enabled drug delivery systems for circadian medicine: bridging direct rhythm modulation and chronotherapy. *RSC Advances*, *15*(38), 31981-32008.